Vivus Weight-Loss Drug Launch In Early Trouble (Updated)

By Adam Feuerstein MOUNTAIN VIEW, Calif. (TheStreet) — Vivus(VVUS_)provided investors with the first detailed looked at the commercial launch of the weight-loss pill Qsymia ...

5 Companies Dominating Diabetes

By Brandy Betz The diabetes treatment business is booming. According to the Centers for Disease Control and Prevention, 25.8 million Americans are affected by diabetes. That’s ...

Strong 1Q from Myriad, Guidance Up

By Zacks Equity Research Myriad Genetics (MYGN) reported earnings per share (‘EPS’) of 36 cents for the first quarter of fiscal 2013. The results improved 24% year over year and ...

Buyout Buzz: The most frequently cited takeover targets in biotech

For years one of the most durable buyout rumors on the market was that GlaxoSmithKline ($GSK) was going to buy Human Genome Sciences. It made a lot of sense. The two companies were ...

Canada, Clinical Trials & A Balancing Act

By Ed Silverman As Canada grapples with its role in the global pharmaceutical industry, a Senate committee has issued a new report that recommends a tougher stance toward the disclosure ...

Which Social Media Groups Distrust Pharma?

By Ed Silverman The increasingly important use of social media by the pharmaceutical industry is not only controversial, but hard to gauge. Although anxious about regulatory scrutiny, ...

The Axe Falls: Bristol-Myers To Cut Nearly 500 Jobs

By Ed Silverman And the parade of layoffs continues. The latest drugmaker to shed some workers is Bristol-Myers Squibb, which plans to eliminate 479 sales reps and related jobs now ...

Wasting Money On Unnecessary Trial Endpoints

By Ed Silverman Nearly one out of every five procedures performed during later stage clinical trials – or more precisely, 18 percent – collect extraneous data and cost drug developers ...

UPDATE 1-Abbott pharma spinoff completes record $14.7bn debt sale

By Andrea Johnson and Christopher Reich NEW YORK, Nov 5 (IFR) – Abbott’s new pharmaceuticals business AbbVie Inc completed the biggest ever dollar-denominated debt issue ...

UPDATE 1-FDA staff highlight heart risk with Novo insulin

(Reuters) – Novo Nordisk’s new ultra long-acting insulin degludec is associated with a higher heart risk than other diabetes treatments, although the size of the risk is ...

Device manufacturer Onyx snapped up by Sparton for $43.25M

By Damian Garde Onyx ($ONXX), a South Dakota manufacturer of medical devices, will soon be part of Sparton Corporation, as the industrial devicemaker has inked a deal to buy the company ...

Becton Dickinson ends FY12 on a sour note as income declines

By Mark Hollmer Becton Dickinson ($BDX) ended its 2012 fiscal year on a sour note, with net income down 3.6% for the fourth-quarter and 8% for the year, as biosciences division sales ...
Page 10 of 93« First...89101112...203040...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS